NVCR NovoCure Ltd
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1645113 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY12.9%
TTM net income YoY31.5%
TTM EPS YoY34.2%
Revenue 3-yr CAGR12.9%
Net income 3-yr CAGR—
Margins
Gross margin77.0%
Operating margin-17.2%
Net margin-16.8%
FCF margin-3.4%
EBITDA margin-14.8%
Returns
ROE-35.2%
ROA-11.1%
ROIC (approx.)-77.8%
Asset turnover0.66x
Leverage & solvency
Liabilities / assets57.7%
Debt / equity0.00x
Current ratio2.49x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.01x
Accruals ratio-11.1%
Payout ratio—
Capex / revenue3.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $193.40M | $183.58M | $174.06M | $174.35M | $167.20M | $158.81M | $154.99M | $161.27M |
| Cost of revenue | $44.53M | $41.11M | $38.93M | $42.16M | $44.73M | $41.47M | $38.52M | $33.47M |
| Gross profit | $148.87M | $142.48M | $135.13M | $132.19M | $122.47M | $117.33M | $116.47M | $127.80M |
| R&D expense | $58.10M | $51.45M | $58.34M | $60.91M | $54.03M | $55.83M | $53.78M | $51.21M |
| SG&A expense | $43.65M | $39.91M | $85.85M | $43.02M | $45.92M | $43.95M | $44.77M | $72.48M |
| Operating income | -$6.17M | -$10.56M | -$67.42M | -$40.39M | -$36.02M | -$39.52M | -$37.87M | -$63.30M |
| Pretax income | -$7.88M | -$12.45M | -$69.26M | -$40.95M | -$30.02M | -$34.98M | -$30.30M | -$55.21M |
| Income tax | $2.56M | $3.21M | $1.88M | -$16.45M | $7.25M | $5.16M | $4.02M | $10.72M |
| Net income | -$10.44M | -$15.66M | -$71.14M | -$24.50M | -$37.27M | -$40.14M | -$34.32M | -$65.92M |
| EBITDA | -$1.75M | -$6.25M | -$63.30M | -$36.17M | -$32.36M | -$36.08M | -$34.54M | -$60.20M |
| EPS (basic) | -0.09 | -0.13 | -0.62 | — | -0.33 | -0.36 | -0.31 | — |
| EPS (diluted) | -0.09 | -0.13 | -0.62 | — | -0.33 | -0.36 | -0.31 | — |
| Weighted avg. shares (diluted) | 116.79M | 116.01M | 114.15M | — | 111.91M | 111.57M | 110.28M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $96.73M | $103.62M | $97.32M | $93.55M | $342.12M | $152.13M | $129.43M | $166.09M |
| Receivables | $108.26M | $99.13M | $93.27M | $89.44M | $85.23M | $89.92M | $84.51M | $74.23M |
| Inventory | $40.60M | $42.22M | $43.46M | $41.11M | $39.10M | $40.21M | $39.47M | $35.09M |
| Current assets | $673.52M | $638.52M | $631.66M | $646.73M | $1.20B | $1.08B | $1.09B | $1.11B |
| PP&E, net | $72.67M | $75.37M | $76.28M | $77.61M | $79.98M | $80.33M | $79.60M | $77.66M |
| Total assets | $828.71M | $795.19M | $787.93M | $804.33M | $1.36B | $1.25B | $1.25B | $1.24B |
| Current liabilities | $270.66M | $220.71M | $217.58M | $223.23M | $776.01M | $749.63M | $743.30M | $756.39M |
| Short-term debt | $25.00M | — | — | $0 | — | — | — | — |
| Long-term debt | — | — | — | $195.05M | — | — | — | $97.30M |
| Total debt | — | — | — | $195.05M | — | — | — | $97.30M |
| Total liabilities | $478.10M | $457.10M | $457.21M | $463.86M | $1.02B | $896.43M | $886.85M | $880.61M |
| Shareholders' equity | $350.61M | $338.09M | $330.72M | $340.47M | $341.33M | $349.44M | $361.96M | $360.18M |
| Net debt | — | — | — | $101.50M | — | — | — | -$68.79M |
| Shares outstanding | 116.91M | 116.44M | 115.82M | 112.49M | 111.98M | 111.80M | 111.48M | 108.52M |
| Cash flow statement | ||||||||
| Operating cash flow | $22.67M | $8.13M | -$13.52M | -$18.00M | $20.57M | -$15.94M | -$35.66M | -$3.45M |
| Capital expenditure | $6.92M | $6.92M | $5.15M | $4.90M | $5.66M | $5.49M | $10.61M | $8.94M |
| Free cash flow | $15.75M | $1.22M | -$18.67M | -$22.90M | $14.92M | -$21.42M | -$46.28M | -$12.39M |
| Investing cash flow | -$23.24M | -$6.38M | $7.75M | $336.33M | $71.44M | $35.99M | -$6.47M | -$22.21M |
| Financing cash flow | $3.64M | $4.55M | -$166,000 | -$559.49M | $100.52M | $2.39M | $5.25M | $2.69M |
| Depreciation & amortization | $4.42M | $4.31M | $4.12M | $4.22M | $3.66M | $3.44M | $3.33M | $3.10M |
| Stock-based compensation | $17.48M | $17.01M | $63.01M | $19.82M | $29.32M | $26.14M | $29.55M | $62.76M |
Free plan shows the latest 8 periods; Pro shows all 49 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.